Cargando…
Off-label use of canakinumab in pediatric rheumatology and rare diseases
Since the first success of interleukin-1 blockade in cryopyrin-associated periodic syndrome, the use of interleukin-1 inhibitors has expanded to other disorders, including off-label indications. In particular, canakinumab has been employed in an off-label fashion in several diseases such as rare mon...
Autores principales: | Del Giudice, Emanuela, Sota, Jurgen, Orlando, Francesca, Picciano, Ludovica, Cimaz, Rolando, Cantarini, Luca, Mauro, Angela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9622922/ https://www.ncbi.nlm.nih.gov/pubmed/36330067 http://dx.doi.org/10.3389/fmed.2022.998281 |
Ejemplares similares
-
Where Is Pediatric Rheumatology Going, and Why a New Section of Frontiers in Pediatrics?
por: Cimaz, Rolando
Publicado: (2020) -
Dealing with COVID-19 in a Pediatric Rheumatology Unit in Italy
por: Costi, Stefania, et al.
Publicado: (2020) -
Real-Life Data on the Efficacy of Canakinumab in Patients with Adult-Onset Still's Disease
por: Vitale, Antonio, et al.
Publicado: (2020) -
Lysosomal storage disorders for the pediatric rheumatologist: the example of mucopolysaccharydoses
por: Cimaz, Rolando, et al.
Publicado: (2015) -
Off-label use of biological agents in the management of uveitis: experience from a pediatric rheumatology centre
por: Campanilho-Marques, Raquel, et al.
Publicado: (2011)